Vertex Pharma disclosed one-year data indicating durable blood glucose control with their stem cell-derived islet cell therapy (zimislecel) in Type 1 diabetes patients. Most participants achieved insulin independence, showcasing potential to transform diabetes management. Enrollment for pivotal studies is ongoing, with expectations for regulatory filings forthcoming.